Table IV.
Outcome summary for all injection-based treatments.
| Study | Mean follow-up, mths (range) |
Primary treatment | Mean number of injections (range) | Cysts, n | Failure, n (%) | Recurrence, n (%) |
|---|---|---|---|---|---|---|
| Puri 2020 |
62 (20 to 111) | Polidocanol | 2.0 (1 to 5) | 55 | 9 (16) | 4 (7) |
| Marie-Hardy 2019 |
51 (16 to 117) | Alcohol | 1.7 (1 to 4) | 55 | 9 (16) | |
| Oliveira 2018 |
46 (24-?) | Calcitonin+ methylprednisolone | 2.8 (1 to 7) | 47 | 4 (9) | 5 (11) |
| Ghanem 2017 |
36 (24 to 71) | Surgiflo + alcohol | 1.1 (1 to 2) | 16 | 5 (31) | |
| Shiels 2016 |
42 (24 to 106) | Doxycyline | 6.4 (2 to 14) | 16 | 0 (0) | 1 (6) |
| George 2009 |
54 (22 to 90) | Ethibloc | 1.2 (1 to 2) | 31 | 2 (6) | |
| Rastogi 2006 |
34 (27 to 80) | Polidocanol | 3.0 (1 to 5) | 72 | 2 (3) | |
| de Gauzy 2005 |
61 (24 to 80) | Ethibloc | 1.1 (1 to 2) | 12 | 3 (25) | |
| Topouchian 2004 |
80 (47 to 116) | Ethibloc | 1.6 (1 to 3) | 15 | 4 (27) | |
| Adamsbaum 2003 |
60 (18 to 132) | Ethibloc | 1.4 (1 to 3) | 17 | 3 (18) |
N/A, not available